Applied Biosystems and Agilent Reach Settlement Agreement Regarding Real-Time PCR Thermal Cyclers

FOSTER CITY, Calif. & SANTA CLARA, Calif.–Applied Biosystems (NYSE:ABI – News), an Applera Corporation business, and Agilent Technologies (NYSE:A – News) today announced that they have entered into a settlement agreement resolving patent infringement lawsuits originally filed by Applera against Stratagene (acquired by Agilent in 2007), alleging infringement of Applera’s real-time thermal cycler instrument patents. The lawsuits resulted in injunctions in Germany and the Netherlands and were pending in the U.S. and France. In connection with the settlement, Agilent has entered into an agreement with Applera to license certain Applera technology relating to Agilent’s real-time thermal cycler instrument business in research-related fields and excluding the field of human in vitro diagnostics. The two companies also announced that Agilent has entered into another agreement with Applera to license certain Applera technology relating to Agilent’s PCR and real-time enzymes and kits. Financial terms of the settlement and related license agreements were not disclosed. These agreements fully resolve all pending disputes between Applera and Stratagene. About Thermal Cyclers and PCR Thermal cyclers are the main instruments for performing polymerase chain reactions (PCR). PCR, used in life science research, is a process in which a segment of a nucleic acid (DNA or RNA) is copied or “amplified” so that the nucleic acid can be more readily analyzed. In real-time PCR, the amplified DNA is detected during, rather than at the end of, the PCR process, a feature that facilitates greater accuracy in important applications, including gene expression quantitation and genotyping. About Agilent Technologies Agilent Technologies Inc. (NYSE:A – News) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.0 billion in fiscal year 2006. Information about Agilent is available on the Web at www.agilent.com. About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.9 billion during fiscal 2006. The Celera Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera maintains a strategic alliance with Abbott for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com. Applied Biosystems Forward Looking Statements Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “should,” “expect,” and “planned,” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) risks that licensing arrangements entered into in connection with the settlement agreement may not result in any future incremental revenue to the Applied Biosystems business; (2) risks associated with lawsuits, arbitrations, investigations, and other legal actions with private parties and governmental entities, particularly involving claims for infringement of patents and other intellectual property rights, and the possibility that Applied Biosystems may need to license intellectual property from third parties to avoid or settle such claims; and (3) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. For Research Use Only. Not for use in diagnostic procedures. ©Copyright 2007. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera and Celera are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.

< | >